Can a memory pill combo shield your brain from radiation?
NCT ID NCT07470606
First seen Apr 16, 2026 · Last updated Jun 23, 2026 · Updated 12 times
Summary
This study tests whether taking memantine (a memory drug) plus raloxifene (a bone drug) can help prevent memory loss in adults receiving radiation for brain tumors. About 108 participants will be followed with MRI scans to see if their brain's memory center stays healthier. The goal is to find a way to preserve thinking skills during cancer treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAIN TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mays Cancer Center, UT Health San Antonio
San Antonio, Texas, 78229, United States
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Memantine and raloxifene
What this could lead to
If successful, this could offer a way to protect memory and thinking skills in people undergoing brain radiation for cancer.
What could go wrong
This is an early phase 2 trial with only 108 participants, so results may not apply to everyone. The drugs may cause side effects or fail to show benefit.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.